ReviewFrontiers in pharmacology2017
Enhancing the Promise of Drug Repositioning through Genetics.
Review in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review.Drug design, development and therapy · 2025Review
- Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients.Frontiers in bioinformatics · 2025Article
- Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.Archives of microbiology · 2024Review
- SGCLDGA: unveiling drug-gene associations through simple graph contrastive learning.Briefings in bioinformatics · 2024Article
- Mapping the functional impact of non-coding regulatory elements in primary T cells through single-cell CRISPR screens.Genome biology · 2024Article
- Repurposing of PSMA-targeted diagnostic and therapeutic agents for the detection and treatment of giant cell tumors of bone.Frontiers in oncology · 2024Article
- Current trends and future prospects of drug repositioning in gastrointestinal oncology.Frontiers in pharmacology · 2023Review
- Artificial intelligence in cancer target identification and drug discovery.Signal transduction and targeted therapy · 2022Review
- Integration of Neighbor Topologies Based on Meta-Paths and Node Attributes for Predicting Drug-Related Diseases.International journal of molecular sciences · 2022Article
- Fine mapping with epigenetic information and 3D structure.Seminars in immunopathology · 2022Review
- Learning from low-rank multimodal representations for predicting disease-drug associations.BMC medical informatics and decision making · 2021Article
- Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- FTY720 Inhibits Expansion of Breast Cancer Stem Cells via PP2A Activation.International journal of molecular sciences · 2021Article
- Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer's Disease: Using the Multiomics Approach.ACS omega · 2021Article
- Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.Current research in pharmacology and drug discovery · 2021Review
- Hybrid attentional memory network for computational drug repositioning.BMC bioinformatics · 2020Article
- An omics perspective on drug target discovery platforms.Briefings in bioinformatics · 2020Article
- Genetic Pleiotropy of Bone-Related Phenotypes: Insights from Osteoporosis.Current osteoporosis reports · 2020Review
- Thioguanine Induces Apoptosis in Triple-Negative Breast Cancer by Regulating PI3K-AKT Pathway.Frontiers in oncology · 2020Article
- Computational Methods for the Integrative Analysis of Genomics and Pharmacological Data.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of new drugs has become challenging as the necessary investments in time and money have increased while drug approval rates have decreased. A potential solution to this problem is drug repositioning which aims to use existing drugs to treat conditions for which they were not originally intended. One approach that may enhance the likelihood of success is to reposition drugs against a target that has a genetic basis. The multitude of genome-wide association studies (GWASs) conducted in recent years represents a large potential pool of novel targets for drug repositioning. Although trait-associated variants identified from GWAS still need to be causally linked to a target gene, recently developed functional genomic techniques, databases, and workflows are helping to remove this bottleneck. The pre-clinical validation of repositioning against these targets also needs to be carefully performed to ensure that findings are not confounded by off-target effects or limitations of the techniques used. Nevertheless, the approaches described in this review have the potential to provide a faster, cheaper and more certain route to clinical approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.